A Randomized, Double Blinded, Active-Controlled Study of Cb-183,315 in Patients with Clostridium-difficile-Associated Diarrhea

-
Investigator: Sarah B. Doernberg, MD
Sponsor: Cubist Pharmaceuticals, Inc.

Location(s): United States

Description

608 patients with Clostridium Difficile Associated Diarrhea (CDAD) will participate in this study and receive either oral vancomycin or CB-183,315 in a blinded fashion. Treatment will last for 10 days and participants will be followed up for at least 40 days and a maximum of 100 days. The purpose of this study is to evaluate how well CB-183,315 treats CDAD as compared to vancomycin.